---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-088411"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-08-12T20:40:26+00:00"
generated_at: "2026-08-12T20:41:11.683659+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics Q2 net loss $5.85M; GX-03 Phase 2 interim data positive, expands study

## Summary
- Net loss $5.85M (-$0.20/share) vs $1.24M (-$0.05) in Q2 2025; cash $10.3M, runway into Q3 2027.
- GX-03 Phase 2 interim: 61.5% vs 8.3% clear/almost clear at Week 4; EASI-75 69.2% vs 25.0% at Week 4.
- Expanded Stage 2 to 120-135 patients including lower EASI; no serious adverse events; enrollment on track for Q4 2026.
- Appointed former FDA Commissioner Stephen Hahn as Executive Clinical and Regulatory Lead on May 18, 2026.
- Plans Phase 2a in hidradenitis suppurativa (~60 patients) targeting first dosing Q2 2027; first peer-reviewed publication May 27, 2026.

## SEC filing metadata
- accession: 0001213900-26-088411
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-08-12T20:40:26+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026088411/0001213900-26-088411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026088411/ea0301772-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-088411
- JSON: https://secwatch.observer/filing/0001213900-26-088411.json
- Plain text: https://secwatch.observer/filing/0001213900-26-088411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.